| Bioactivity | TNG348 is an oral inhibitor of the deubiquitinating enzyme USP1 that can be studied in BRCA1/2 mutated or HRD+ cancers[1]. |
| CAS | 2839740-79-1 |
| Formula | C27H23F6N9O |
| Molar Mass | 603.52 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Simoneau A, et al. Abstract B054: TNG348, a selective USP1 inhibitor, shows strong preclinical combination activity with PARP inhibitors and other agents targeting DNA repair[J]. Molecular Cancer Therapeutics, 2023, 22(12_Supplement): B054-B054. |